2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Adverse Events, Biological Processes, Apoptosis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3572 Orelabrutinib, obinutuzumab, and lenalidomide induced deep responses and immune remodeling in untreated marginal zone lymphoma: Full-cohort results of a phase II study

Wei Wang, Hongmei Jing2, Zhitao Ying3, Wenrong Huang, Professor/Chief Physician4, Huizhen He5, Yan Zhang, MD6, Jian Li, MD7
1 Peking Union Medical College Hospital, Beijing, China
2 Peking University Third Hospital, Beijing, China
3 Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
4 The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
5 Beijing Tongren Hospital, Beijing, China
6 Peking Union Medical College Hospital, Beijing, China
7 Peking Union Medical College Hospital, Beijing, China

Background: Marginal zone lymphoma (MZL) is biologically heterogeneous, and frontline treatment remains poorly standardized. Targeted regimens without chemotherapy may be particularly suited to this disease. We evaluated orelabrutinib, obinutuzumab, and lenalidomide as fixed-duration therapy in treatment-naive MZL. Here, we report the full-cohort results of this prospective phase II study (NCT06454968).

Methods: Newly diagnosed adult MZL patients who required systemic therapy were enrolled. Patients received six 21-day induction cycles of orelabrutinib, obinutuzumab, and lenalidomide, followed by six 28-day cycles of orelabrutinib monotherapy. The primary endpoint was complete response rate (CRR). Secondary endpoints included ORR, duration of response, uMRD rate in SMZL, and safety. Landmark response analyses included all patients who completed evaluation at each protocol-defined time point. Patients who discontinued earlier but had a response assessment were included.

Results: As of July 16, 2026, forty-eight patients were enrolled. Median age was 65.5 years (range, 36-81), and 29 patients (60.4%) were female. Subtypes included SMZL (n=21, 43.8%), MALT/EMZL (n=20, 41.7%), disseminated MZL (n=6, 12.5%), and nodal MZL (n=1, 2.1%). Forty-five (93.8%) had Ann Arbor stage IV disease. CRR was 63.4% (26/41) at cycle 3, 75.0% (27/36) at cycle 6, and 78.6% (22/28) at the end of treatment (EOT). ORR was 90.2% (37/41), 80.6% (29/36), and 82.1% (23/28), respectively. Best ORR was 88.1% (37/42), with a best CR rate of 76.2% (32/42). With a median follow-up of 10.6 months, median PFS and OS were not reached; 12-month PFS and OS were 85.3% and 97.1%. Of 11 SMZL patients with MRD data, 7 (63.6%) achieved uMRD. Among 19 SMZL patients with baseline NGS, responses were observed across genetic subtypes, including 3 TP53-mutated cases (2 CR, 1 PR). Common adverse events included petechiae/skin purpura (31.2%), infusion-related reactions (27.1%), neutropenia (22.9%), thrombocytopenia (20.8%), and rash (20.8%). Grade 3 or higher events were mainly hematologic, infusion-related, cutaneous, and infectious. Seven patients discontinued early (some after achieving response); one death occurred after large-cell transformation. No treatment-related deaths were reported. In 13 paired immune-phenotyping samples, treatment induced near-complete circulating CD19+ B-cell depletion, expansion of T-cell and NK-cell compartments, enrichment of CD8+ effector/memory phenotypes, and reduced PD1+ T cells.

Conclusion: In this full-enrollment analysis, the fixed-duration Orelabrutinib-based regimen produced high and deepening responses, encouraging early survival, and immune remodeling in untreated MZL. These results support its continued evaluation as a frontline chemotherapy-free option.

Wei Wang: No relevant conflicts of interest to declare.